North America Cold Sore Treatment (for HSV 1 Virus) Market – Industry Trends and Forecast to 2030

North America Cold Sore Treatment (for HSV 1 Virus) Market Analysis and Insights

Increasing prevalence and incidences of cold sore infections have enhanced the market demand. The rising healthcare expenditure for better health services also contributes to market growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in investments in pharmaceutical R&D and life sciences research also contributes to the rising demand for cold sore treatment.

The North America cold sore treatment (for HSV 1 virus) market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activities for launching novel products in the market. The proliferation in modes of transmission of HSV is further boosting market growth. However, a dearth of awareness about the onset and symptoms of cold sore and its treatment might hamper the market growth in the forecast period.

The North America cold sore treatment (for HSV 1 virus) market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyzes that the market is growing with a CAGR of 5.6% in the forecast period of 2023 to 2030 and is expected to reach USD 690.51 million by 2030 from USD 446.54 million in 2022.

Market Definition

Cold sores or oral herpes are small blisters-like abrasions that occur due to the infection caused by the Herpes Simplex Virus (HSV). Cold sores generally occur on the face, around the lips, chin, cheeks, and nostrils. They generally cause pain and itching before they burst. HSV is one of the most common viruses found to affect the global population and it is endemic throughout the world. Up to 90% of people around the world have at least one form of HSV. It generally infects the pediatric population worldwide, but according to WHO, people aged 30-49 are at higher risk now for catching the virus, and the prevalence of HSV increases with age.

North America Cold Sore Treatment (for HSV 1 Virus) Market Dynamics

DRIVERS

• Growing Prevalence of Cold Sore Infection

A group of small, hurting blisters caused by the Herpes Simplex Virus (HSV) is called cold sores. They are also called fever blisters or oral herpes. HSV is one of the most common viruses found to affect the global population and is endemic worldwide.

For instance,

• According to WHO, people under 50 infected with HSV-1 are estimated to be more than 3.7 billion globally (67%)

• According to the Centers for Disease Control and Prevention (CDC), data from the National Health and Nutrition Examination Survey showed that the prevalence of HSV-1 is found to be more in women as compared to men globally. The prevalence of HSV also increases with age.

• According to CDC, HSV-1 prevalence in the U.S. among people aged 0-49 in 2012 includes 178 million women, which means 49% of women population

With these instances, we can conclude that the growing prevalence of cold sore infections is driving the market growth.

• Proliferation in Modes of Transmission of Herpes Simplex Virus

An infectious virus can be transmitted in different modes, from its natural reservoir to a susceptible host. The spread of HSV infection relies on the intimate, personal interaction of a susceptible person with someone who excretes HSV transmission modes have different classifications, which include direct and indirect transmission.

HSV is commonly transmitted through direct transmission, including direct contact or droplet spread. The primary mode of HSV-1 transmission is via oral-to-oral contact inducing infection with oral herpes, by contact with the HSV in saliva, sores, and surfaces in or around the mouth. Also, unhygienic practices, unprotected sexual intercourse, and oral sex are the major modes coming up which are increasing the transmission of HSV among people. Moreover, HSV can be transmitted via contact, such as kissing, eating from the same utensils, sharing cups, towels, or from toilet seats, and sharing lip balm. Thus, the increase in infectious disease transmission modes is anticipated to drive market growth.

OPPORTUNITY

• Increasing Use of Cold Sore Patches

The increasing cases of cold sores have created numerous opportunities for the market players and potentially surged the demand for treatment options required to treat the HSV-1 infection or associated disease. Due to this reason, various key market players are investing more in HSV research to come up with novel treatment options.

Several technological advancements are taking place for the treatment of cold sores, including all medical research aimed at introducing new technologies (vaccines, therapy, drugs, and patches) for the treatment of cold sores. Patches are consistently in demand for their effectiveness against cold sores.

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for market growth in the forecast period of 2023-2030.

RESTRAINT/CHALLENGE

• The Dearth of Awareness about the Onset and Symptoms of Cold Sore and its Treatment

The dearth of awareness about the onset and symptoms of cold sore and the patent termination of some of the marketed drugs will impede the market growth rate. Additionally, side effects associated with medications used for treating cold sores will further challenge the market growth.

Recent Developments

• In October 2022, GSK plc. and Tempus, a U.S.-based precision medicine company, entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment, and identify drug targets. This will contribute to GSK’s R&D success rate and provide patients with more personalized treatment faster.
• In July 2022, Haleon Group of Companies announced the completion of the spin-off of the healthcare business from GSK Group to Haleon Group. Haleon is the world's leading consumer health company, with brands trusted by millions of consumers worldwide. Its product range includes five main categories- oral health, pain relief, respiratory health, digestive health, and others, as well as vitamins, minerals, and dietary supplements (VMS). Its long-standing brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, Parodontax, and Centrum are based on sound science, innovation, and a deep understanding of people.

North America Cold Sore Treatment (for HSV 1 Virus) Market Scope

The North America cold sore treatment (for HSV 1 virus) market is segmented into product type, route of administration, type, gender, drug type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Medications
• Ointments
• Creams
• Medicated Lip Balms
• Cold Sore Patches
• Non-Medicated Products

Based on product type, the market is segmented into medications, ointments, creams, medicated lip balms, cold sore patches, and non-medicated products.

Route of Administration

• Oral
• Topical
• Others

Based on route of administration, the market is segmented into oral, topical, and others.

Type

• Prescription Drugs
• Over The Counter (OTC) Drugs

Based on type, the market is segmented into prescription drugs and Over The Counter (OTC) drugs.

Gender

• Male
• Female

Based on gender, the market is segmented into male and female.

Drug Type

• Branded
• Generics

Based on drug type, the market is segmented into branded and generics.

End User

• Hospitals
• Specialty Clinics
• Homecare Setting
• Others

Based on end user, the market is segmented into hospitals, specialty clinics, homecare setting, and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

North America Cold Sore Treatment (for HSV 1 Virus) Market Regional Analysis/Insights     

The North America cold sore treatment (for HSV 1 virus) market is analyzed and market size insights and trends are provided by country, product type, route of administration, type, gender, drug type, end user, and distribution channel as referenced above.

The U.S. is dominating the market in North America in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of cold sore infections in the region and rapid R&D, which is boosting market growth.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые и заменяющие продажи, демографические данные страны, эпидемиология заболеваний и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность брендов Северной Америки и проблемы, возникающие из-за высокой конкуренции со стороны местных и отечественных брендов, а также влияние каналов продаж.

Конкурентная среда и анализ доли рынка лечения герпеса (вируса HSV 1) в Северной Америке

Конкурентная среда рынка лечения герпеса (вируса HSV 1) в Северной Америке содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в НИОКР, новых рыночных инициативах, присутствии в Северной Америке, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта и доминировании в применении. Приведенные выше данные относятся только к фокусу компаний на рынке.

Некоторые из основных игроков, работающих на рынке лечения герпеса (вируса HSV 1) в Северной Америке, включают GSK plc., Novartis AG, Viatris Inc., Hikma Pharmaceuticals PLC, HRA Pharma, Quantum Health, URGO, Apotex Inc., Church & Dwight Co., Inc., Bausch Health Companies Inc., Zydus Pharmaceuticals Inc., Haleon Group of Companies, Amparo medical Technologies, Teva Pharmaceuticals USA, Inc., Carma Labs Inc. и Blistex Inc. и другие.

SKU-60513